Global DNA Microarray Market By Type (Oligonucleotide Dna Microarrays (Odna), And Complementary Dna Microarrays (Cdna)), By Application (Gene Expression, Genotyping, Genome Cytogenetics, And Other), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)

                                          
Report updated on 11th September, 2021: Global DNA Microarray Market By Type (Oligonucleotide Dna Microarrays (Odna), And Complementary Dna Microarrays (Cdna)), By Application (Gene Expression, Genotyping, Genome Cytogenetics, And Other), By Region and Key Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2021-2030 (Includes Business Impact of COVID-19)
Trusted Business Insights has published a comprehensive market research report on, Global DNA Microarray Market by Product Type (Oligonucleotide DNA Microarrays (oDNA) & Complementary DNA Microarrays (cDNA)), By Application(Gene Expression, Genotyping, Drug Discovery & Other Application), and by Region -Global Forecast to 2030, which offers a holistic view of the global DNA Microarray market through systematic segmentation that covers every aspect of the target market.

The global DNA Microarray market is projected to be US$ 2891.8 Mn in 2020 to reach US$ 7511.6 Mn by 2030 at a CAGR of 10.1%.

Every living organism contains DNA, a long molecule that contains all information required for building and functioning of life form. An array is a systematically arranged sample where the matching of a known and unknown DNA sample is done. Microarray helps in analysis of gene expression with the information contain within a genome. DNA microarray is a large segment of the microarray market. DNA microarray is an innovative and versatile technology which is used for multiple gene expression analysis in a single reaction by collecting of microscopic DNA spots attached to a solid surface usually glass, silicon chip or nylon membrane. Moreover, generating probes on the solid surface requires substantial expertise and technical tricks. Microarray is used for measuring the expression levels of a large number of genes. Furthermore, this technology has empowered the scientist to understand the fundamental aspects of underlining the development of life and also explore generic causes of anomalies occurring in the functioning of a living organism.

Growing chronic diseases like cancer, asthma, diabetes, and depression have led to an increase in R&D, and drug discovery activities for prevention that are directly influencing the demand for DNA microarray market.


Global DNA Microarray Market Revenue (US$ Mn), 2019“2029


However, DNA microarray technology requires substantial expertise, and technical tricks, therefore, lack of skilled professionals, particularly in developing region is expected to obstruct the growth of the DNA microarray market. Nonetheless, innovation in a microarray software for fast, efficient design of specific oligos for making whole-genome arrays, tiling arrays, and resequencing arrays are trending in the developed market like North America and Europe and is expected to create new opportunity in the emerging regions like South America.

Global DNA Microarray market is segmented based on product type, application, and region. Based on product type, the market is segmented into Oligonucleotide DNA Microarrays (oDNA) & Complementary DNA Microarrays (cDNA). The Oligonucleotide DNA Microarrays (oDNA) segment accounts for the majority share and is expected to register highest growth over forecast period, followed by Complementary DNA Microarrays (cDNA) segment. On the basis of application, the market is segmented into Gene Expression, Genotyping, Drug Discovery & Other Application. The gene expression segment accounts for a majority share in the global DNA Microarray market.


Global DNA Microarray Market By Application, 2019


Based on region, the market is segmented into North America, Europe, APAC, South America and Middle East Africa. North America accounts for the majority share in the global DNA Microarray market, growing chronic diseases. APAC is expected to register highest growth rate over forecast period. Regions such as Europe, South America, and MEA are expected to register stable growth over the forecast period.

The research report on the global DNA Microarray market includes profiles of some of the major companies such as Illumina, Inc., MERCK Kommanditgesellschaft auf Aktien, Agilent Technologies, Inc., Thermo Fisher Scientific Inc., Roche Holding AG, SCIENION AG and Applied Microarrays, Inc.



Below are the active patents related to DNA Microarray Market.


Patent Number: US20060030032A1

Three-phase tilting agitator for microarrays

Abstract

A low-cost, easy to operate, three-phase tilting agitator for microarrays, including large area microarrays, provides experimentally verified improvements in hybridization intensity and uniformity. Motion is coupled from a single motor to a sample holder via three suspension tethers. The microarrays may be immersed in a water bath during agitation to maintain a temperature for the hybridization reaction. The use of traditional cover slips for the microarrays minimizes the volume requirement for target sample solution.

Application File Date: 2005-07-29

Application Granted Date: 2009-08-25

Current Assignee: Tsinghua University,  CapitalBio Technology Co Ltd

Patent Number: US7083975B2

Microarray synthesis instrument and method

Abstract

During the light illumination period of a monomer addition cycle in synthesizing an DNA microarray, undesirable reflections of illumination light from various interfaces that the illumination light passes through near the synthesis surface of the substrate may reduce the light-dark contrast, and negatively affect the precision and resolution of the microarray synthesis. The present invention provides an flow cell that reduces the undesired reflections by constructing certain flow cell structures with materials that have similar refractive indexes as that of the solution that is in the oligomer synthesis chamber during the illumination period and/or constructing certain flow cell structures or covering the structures with a layer of a material that has a high extinction coefficient.

Application File Date: 2002-02-01

Application Granted Date: 2006-08-01

Current Assignee: Roche Sequencing Solutions Inc

Patent Number: US20070037274A1

Microarray synthesis instrument and method

Abstract

During the light illumination period of a monomer addition cycle in synthesizing an DNA microarray, undesirable reflections of illumination light from various interfaces that the illumination light passes through near the synthesis surface of the substrate may reduce the light-dark contrast, and negatively affect the precision and resolution of the microarray synthesis. The present invention provides an flow cell that reduces the undesired reflections by constructing certain flow cell structures with materials that have similar refractive indexes as that of the solution that is in the oligomer synthesis chamber during the illumination period and/or constructing certain flow cell structures or covering the structures with a layer of a material that has a high extinction coefficient.

Application File Date: 2006-10-27

Application Granted Date: 2011-09-27

Inventor: Roland GreenAlan PitasFrancesco Cerrina

Key Market Segments:

By Type

  
Oligonucleotide DNA Microarrays (oDNA)
  
Complementary DNA Microarrays (cDNA)

By Application

  
Gene expression
  
Genotyping
  
Genome cytogenetics
  
Other


Key Market Players included in the report:


  
Affymetrix
  
Agilent Technologies Inc. (US)
  
Applied Microarrays
  
Arrayit Corporation
  
BioGenex
  
Biometrix Technology
  
Bio-Rad Laboratories Inc. (US).
  
GE Healthcare (US)
  
Illumina Inc. (US)
  
Merck KGaA
  
Microarrays Inc.
  
Molecular Devices (US)
  
PerkinElmer Inc. (US)
  
Phalanx Biotech.
  
QIAGEN
  
Roche Holding AG
  
Roche NimbleGen
  
Savyon Diagnostics
  
Scienion AG
  
Sengenics
  
Thermo Fisher Scientific Inc. (US)
  
WaferGen


Below are the key development related to DNA Microarray Market in 2020 and 2021.


Jun 2021: Twist Bioscience Acquires NGS Library Preparation Maker iGenomX. Twist Bioscience Corporation (Nasdaq: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, announced the acquisition of iGenomX, a company offering multiplex library preparation tools for next-generation sequencing (NGS) workflows. The acquisition is expected to enhance Twist’s capabilities to support multiplex sequencing preparations across multiple markets and to accelerate Twist’s conversion of customers from static microarray platforms to genotyping by sequencing workflows. “The iGenomX team built a robust PCR-like workflow for ultra-high throughput library construction that will further enable customers to convert from SNP microarray to an NGS-based approach,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. Source

March 2021: Hologic Acquires European MDx Firm Diagenode for Approximately $159M. Hologic on Monday announced it has acquired Diagenode, a privately held, European developer and manufacturer of molecular diagnostic assays and epigenetics products, for approximately $159 million. Liege, Belgium-based Diagenode markets more than 30 real-time PCR tests that are CE-marked for the detection of bacteria, parasites, and viruses involved in sexually transmitted infections, respiratory diseases, meningitis, and gastroenteritis.Marlborough, Massachusetts-based Hologic said Diagenode previously collaborated with it to develop Panther Fusion assays for group B Streptococcus and Bordetella. The European firm also has an epigenetics portfolio that consists of devices, kits, reagents, antibodies, and services to aid in the analysis of DNA and RNA, Hologic said. Source

Jan 2021: Merck Acquires AmpTec to Expand mRNA Capabilities for Vaccines, Treatments and Diagnostics. Adds to Mercks lipid manufacturing expertise, providing an integrated offering across mRNA value chain. AmpTecs differentiated polymerase chain reaction (PCR)-based technology has shown to have advantages over other technologies for mRNA manufacturing.Diagnostics business focused on producing customized long RNAs and DNAs for in vitro diagnostics, complements existing Merck portfolio. Merck, a leading science and technology company, announced the acquisition of AmpTec, a leading Hamburg, Germany-based, mRNA contract development and manufacturing organization (CDMO). The deal strengthens Mercks capabilities to develop and manufacture mRNA for its customers for use in vaccines, treatments and diagnostics applicable in Covid-19 and many other diseases. Financial terms were not disclosed. Source